Go to:
Top news
Following the validation of its new vaccine and manufacturing platforms, Verovaccines is expanding its portfolio with new mono- and combination vaccines.
GO-Bio initial
GO-Bio next
Selection panel GO-Bio initial
Selection panel GO-Bio next
FAQ GO-Bio initial
FAQ GO-Bio next
Successes of the GO-Bio programme
Talking about
Platform technology for enzymatic de novo DNA synthesis
News
Use of natural killer cells for cancer immunotherapy
Projects
Go-Bio initial Bootcamp
Endoprosthesis implantation
Gründungsgespräche
Synthetic biology against neurodegenerative diseases
